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Abstract
We conducted a systematic review of the published literature to examine the impact of new 
vaccine introduction on countries’ immunization and broader health systems. Six publication 
databases were searched using 104 vaccine and health system-related search terms. The search 
yielded 15,795 unique articles dating from December 31, 1911 to September 29, 2010. Based on 
review of the title and abstract, 654 (4%) of these articles were found to be potentially relevant 
and were referred for full review. After full review, 130 articles were found to be relevant and 
included in the analysis. These articles represented vaccines introduced to protect against 10 
different diseases (hepatitis A, hepatitis B, Haemophilus influenzae type b disease, human 
papilloma virus infection, influenza, Japanese encephalitis, meningococcal meningitis, 
Streptococcus pneumoniae disease, rotavirus diarrhea and typhoid), in various formulations and 
combinations. Most reviewed articles (97 [75%]) reported experiences in high-income countries. 
New vaccine introduction was most efficient when the vaccine was introduced into an existing 
delivery platform and when introduced in combination with a vaccine already in the routine 
childhood immunization schedule (i.e., as a combination vaccine). New vaccine introduction did 
not impact coverage of vaccines already included in the routine childhood immunization schedule. 
The need for increased cold chain capacity was frequently reported. New vaccines facilitated the 
introduction and widespread use of auto-disable syringes into the immunization and the broader 
health systems. The importance of training and education for health care workers and social 
mobilization was frequently noted. There was evidence in high-income countries that new vaccine 
introduction was associated with reduced health-care costs. Future evaluations of new vaccine 
introductions should include the systematic and objective assessment of the impacts on a country’s 
immunization system and broader health system, especially in lower-income countries.
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1. Introduction
The Expanded Program on Immunization (EPI) was established by the World Health 
Organization (WHO) in 1974 to provide protection against six vaccine-preventable diseases 
(tuberculosis, poliomyelitis, diphtheria, tetanus, pertussis, and measles) through routine 
infant immunization. Since then, many new vaccines have become available, and global 
public funding for immunization, including the GAVI Alliance, has increased accessibility 
to these vaccines [1]. Most of the new vaccines, including hepatitis B (HepB) vaccine, 
Haemophilus influenzae type B (Hib) vaccine, pneumococcal conjugate vaccine (PCV), and 
rotavirus (RV) vaccine are intended to be included in the routine childhood immunization 
schedule. Other new vaccines, such as human papillomavirus (HPV) vaccine meningococcal 
vaccine, yellow fever vaccine, and typhoid vaccine are intended for older or at-risk 
populations.
The introduction of a new vaccine can have both positive and negative impacts on the 
immunization system and the broader health system. It may provide opportunities and 
resources to strengthen an existing system, or it may add stress to an already weak 
infrastructure. Based on a request in 2010 from the Strategic Advisory Group of Experts 
(SAGE) on Immunization that guides the World Health Organization (WHO) on global 
immunization policies, we conducted a systematic review of the published literature to 
examine evidence of impact of new vaccine introduction on health and immunization 
systems reported in the medical literature.
2. Methods
2.1. Search strategy
We developed search terms to identify articles that included information describing the 
impact of new vaccine introduction on immunization systems and health systems [2] (Table 
1). The terms were selected to be inclusive and were developed with input from 
immunization experts. The search terms were divided into two broad categories: (1) 
vaccines and (2) immunization and health systems, and databases were searched to identify 
articles captured by at least one search term in each category (Table 1).
We searched seven publication databases (Medline®, EmbaseTM, Nursing Update, West 
African Journal of Nursing, CINAHL®, Web of Science®, and Global Health) that are 
relevant to vaccines and immunization programs, and are likely to contain reports from low 
income countries. We attempted to use identical terms to search each database; however, as 
each database had certain specifications, it was sometimes necessary to modify some terms. 
We limited the search to reports involving human subjects, published in any language. The 
final search date was September 29, 2010 and was not limited to a beginning year.
Hyde et al. Page 2














We reviewed the title and abstract of each article identified using the search strategy to 
determine whether the article was potentially relevant (i.e., contained quantitative or 
qualitative information on the impact of new vaccine introduction on the immunization 
system, the broader health system, or both). Potentially relevant articles were referred for a 
full abstraction. Articles that discussed disease incidence, disease burden, vaccination 
coverage, serotype replacement, immunization campaigns, or adverse events following 
immunization were included if they contained data or discussion of vaccine impact on the 
health or immunization system and assessed outcome within the first five years after vaccine 
introduction, unless the assessed outcome manifested more than five years after vaccine 
introduction (e.g., HepB vaccine and hepatocellular carcinoma or cirrhosis, or HPV vaccine 
and cervical cancer). Cost effectiveness studies were considered if they included real-time 
data, and real situations and savings and were not based on results of modeling. Expert 
opinion articles were included if data were reported. We excluded clinical trials, because 
they did not show impact on the immunization and health systems following vaccine 
introduction.
2.3. Abstraction process
We used EndNote X3.0.1S (Thompson Reuters) to organize and track the articles, adding 
databases sequentially beginning with Medline, and performing automated and manual de-
duplication following the addition of each subsequent database. Each article was reviewed to 
determine if it addressed the impact of the vaccine introduction on the immunization and 
health system. Sixteen immunization experts from the World Health Organization (WHO), 
the Centers for Disease Control and Prevention (CDC), The United Nations Children’s Fund 
(UNICEF), the London School of Hygiene and Tropical Medicine and Hygiene (LSHTM), 
the Program for Appropriate Technology in Health (PATH), and Maternal and Child Health 
Integrated Program (MCHIP) participated in the abstraction process. Information from 
relevant articles was abstracted using a Microsoft Access® 2007 data collection form and 
were organized according to the WHO Framework for Action (Fig. 1); this framework was 
created by WHO in 2007 to promote a common understanding of health care systems by 
providing a systematic means for considering the essential functions [2]. The Framework 
comprises six building blocks: service delivery; health workforce; information; medical 
products, vaccines and technologies; financing; and leadership and governance. Countries 
were grouped by gross national income into categories according to the World Bank Atlas 
Method [http://data.worldbank.org/about/country-classifications/country-and-lending-
groups]. Non-English articles were reviewed and abstracted by native speakers, whenever 
possible. A random sample of 10% of the articles were reviewed and abstracted by a second 
reviewer. If discordance was found, the article was reviewed by the first author to resolve 
discrepancies.
3. Results
3.1. Search and abstraction
The search yielded 24,768 articles from December 31, 1911 to September 29, 2010, among 
which 8973 (36%) were found to be duplicates (Fig. 2). Reviewers applied the inclusion 
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criteria to the remaining 15,795 titles and abstracts. Among these, 654 (4%) articles met the 
inclusion criteria and were referred for full abstraction; 49 (7%) of these were in languages 
other than English. One hundred twenty-nine (20%) of the 654 abstracted articles were 
found to be relevant for the analysis. In addition, one key article known to the authors that 
was not identified by the systematic search of the published literature was included, 
resulting in a total of 130.
3.2. General overview
Among the 130 studies included in this review (Table 2), 97 (75%) were from high income 
countries; 21 (16%) were from middle income countries; and 4 (3%) were from low income 
countries. The studies included vaccines targeting 10 diseases (hepatitis A (3 [2%]), 
hepatitis B (24 [19%]), Hib disease (28 [22%]), HPV infection (13 [10%]), influenza (1 
[1%]), Japanese encephalitis (1 [1%]), meningococcal meningitis (17 [13%]), Streptococcus 
pneumoniae disease (28 [22%]), rotavirus diarrhea (14 [11%]) and typhoid (2 [2%])). 
Multiple vaccine formulations (i.e., antigens, adjuvants, stabilizers, preservatives and other 
components) and vaccine combinations were represented in the studies. Overall, 64 (56%) 
studies considered vaccine introductions that took place between 2000 and 2008.
3.3. Service delivery
In a number of countries, introduction of the new vaccines required new delivery strategies 
or modification of existing delivery strategies. While many new vaccines have been 
introduced through routine vaccination programs and mass campaigns, other delivery 
strategies, including one-time catch up vaccination, school-based vaccination, or a 
combination of strategies, depending on the vaccine and age recommendation for 
vaccination have been utilized to introduce new vaccines [3-10]. Novel delivery strategies, 
and the need for social promotion and education about the new vaccine’s safety and 
potential adverse events, may also affect the delivery of other immunization and health 
services. In several high and middle income countries coverage with existing vaccines 
administered through routine childhood or school-based strategies increased (Australia, 
Germany and Peru) or remained the same (Thailand and the United States) when new 
vaccines were introduced [11-16]. In Canada, offering PCV at no cost helped to remove 
existing inequities in PCV distribution [17], increased PCV acceptance and improved on-
time vaccination [17,18]. Australia’s government-funded HPV vaccination strategy 
consisted of school-based routine vaccination of 12-year-old girls, including a 2-year catch-
up strategy [5]. The catch-up strategy for 13–18 year olds was largely school-based, and for 
18–26-year-old women was carried out by general practitioners. The general practitioner 
visit was also intended to provide an opportunity for physicians to broaden sexual health 
education and discuss cervical cancer prevention [5]. However, ensuring completion of the 
series for those who missed school-based vaccination required additional efforts, including 
coordination with general practitioners, additional mop-up campaigns at the end of the year, 
or establishing an individual recall system.
Communication and education activities were often coupled with delivery of new vaccines. 
Social mobilization to publicize vaccination – including through mothers’ clubs and 
professional organizations – was part of successful efforts to ensure wide acceptance of 
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HepB vaccine in Singapore [19], China [20], Taiwan [21] and Peru [15], and of Hib vaccine 
in Uruguay, Chile, Qatar, and Kuwait [22]. Introduction of HPV vaccine in the UK involved 
engagement of multiple stakeholders and was facilitated through the establishment of an 
HPV vaccine implementation group [23]. Knowledge and education about the disease and 
the vaccine, including safety issues, aided the successful introduction of Hib [24] vaccine 
and HepB vaccine [25] vaccine in Canada and Hib in the United Kingdom [26]. In the 
United States and Canada, HPV vaccine, in contrast to other routinely recommended 
childhood immunizations, was actively marketed through direct consumer advertising and 
public awareness campaigns that targeted legislators and policy makers in addition to 
consumers [27]. In the United Kingdom, funding for media communication about 
meningococcal conjugate C vaccine was included in the budget for vaccine introduction 
[28]. Because adding a new immunization can result in an additional injection during a 
routine childhood vaccination visit, immunization planners in Israel chose a Hib vaccine 
with a 2-dose rather than a 3-dose series, in part to avoid three injections at the 6 month visit 
[29]. In Australia, some vaccine providers were reported to be reluctant to administer three 
injections at one time, resulting in lower uptake of PCV in a high-risk population [30].
3.4. Health workforce
There was variability in the impact of new vaccine introduction on the health workforce. In 
settings where vaccination was introduced into regularly scheduled clinics, little impact on 
staffing and appointment times was observed, as was the case with Hib vaccine introduction 
in Sweden [31], HPV vaccine introduction in Australia [32], and PCV introduction in the 
United States [11]. Vaccine introduction into adolescent and adult immunization programs 
sometimes required additional staff or adjustment of appointment times: in Scotland, adding 
pneumococcal vaccine to appointments for influenza vaccination among older adults 
increased consultation times by about 2 min [33]. Additional staff were needed for HPV 
vaccine introduction in the United Kingdom [34], where public health nurses, pediatric 
nurses, health visitors, and managers were recruited into teams, and additional funding was 
made available to address a shortage of school nurse vaccinators. Lack of staff was reported 
as a barrier to HPV vaccine introduction in remote areas of Australia [5], and HepB vaccine 
introduction in juvenile justice facilities in the United States [35].
Training of health staff at national, regional and local levels was required for successful 
HepB vaccine introduction in China [36] and Zimbabwe [37], hepatitis A and Japanese 
encephalitis (JE) vaccine in China [38], Hib vaccine in the Americas [39,40], and 
meningococcal polysaccharide vaccine in Egypt [3]. When the new vaccine was introduced 
as a combination product that included a vaccine already used in the childhood vaccination 
schedule [22], training was relatively straightforward. In Zimbabwe the introduction of 
HepB vaccine also included development of communication materials, and training on 
community mobilization activities [37]. In Indonesia, training, and periodic re-training in the 
local language were needed to successfully implement the school-based typhoid program 
[10]. Continuing education was conducted in Italy to promote the birth dose of HepB 
vaccine [41]. To ensure funding for training, the vaccine introduction budget for HepB and 
Hib vaccines in Ethiopia included a training and education component [42].
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In other countries, vaccine introduction stimulated the development of new surveillance or 
vaccine registry systems, including comprehensive surveillance for meningococcal 
meningitis in the United Kingdom [4], pediatric invasive pneumococcal disease in Canada 
[43], hepatitis B virus-associated nephropathy in South Africa [44], and an HPV 
immunization registry in Australia [16,45]. In Chile and Uruguay, Hib case definitions and 
disease reporting forms were standardized, and a technology transfer program was 
developed following Hib vaccine introduction [39]. A national immunization register, 
implemented at the same time as a meningococcal conjugate B vaccination campaign in 
New Zealand, was used to monitor coverage, safety and effectiveness assessments [46]. In 
Australia’s HPV vaccination program, a time-limited incentive payment of $6 per 
notification of vaccination was offered to general practitioners to improve completeness of 
the vaccine register [45]. In China [47,48], Malawi [49], South Africa [50], Nicaragua [51], 
Canada [52] and Egypt [3], existing disease surveillance systems were used for impact 
evaluation, policy formulation, and program advocacy related to immunization against 
HepB [48], JE [47], Hib [49,50], rotavirus diarrhea [51], pneumococcal pneumonia [52] and 
meningococcal meningitis [3,3].
3.6. Medical products, vaccines and technologies
The availability and use of new technologies, including combination vaccines and auto-
disable (AD) syringes, had an impact on the immunization system. In Chile (DTP-Hib) [53], 
the United States (DTP-Hib) [54] and Zimbabwe (DTP-HepB) [37], use of combination 
vaccines resulted in fewer injections, and the need for fewer needles and syringes; lower 
administrative costs; and reduced storage capacity, compared with introducing a new 
vaccine as a separate vaccine injection. Introduction of DTP-Hib vaccine in The Gambia; 
however, resulted in initial interruption of routine DTP immunization due to irregular supply 
of the combination vaccine [55].
In some instances, introduction of new vaccines created additional requirements for cold 
chain and logistics systems. In Ethiopia, the replacement of 10-dose vials of whole cell 
diphtheria–tetanus–pertussis (DTwP) vaccine with single-dose vials of pentavalent (DTwP–
Hep B–Hib) increased transport and cold chain requirements [42]. The need for additional 
cold chain capacity was also reported for rotavirus in several Latin American countries [56], 
hepatitis A and B vaccine introduction in China[20,38], HPV vaccine introduction in the 
United States [35], and 23-valent pneumococcal polysaccharide vaccine (PPV23) for older 
adults in Scotland [33]. In other cases, as was the case for Hib introduction, existing 
infrastructure was adequate for introduction [39].
As part of new vaccine introduction, AD syringes, safety boxes, and injection safety policies 
were introduced into immunization programs. In an evaluation of 58 countries eligible for 
funding from the GAVI Alliance that received injection safety support, all but two continued 
exclusive use of AD syringes and safety boxes after funding ended [57,58]. In some 
countries, the use of AD syringes, safety boxes, and injection safety policies were expanded 
beyond the immunization program to other health services. Most countries were able to 
continue the use of AD syringes after GAVI funding for injection safety support ended.
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3.7. Financing and sustainability
Cost was a consideration in planning new vaccine introduction, including introduction in 
developed countries [57]. Utilizing existing infrastructure or combination vaccines reduced 
the costs for introduction, as was documented with introduction of DTP-Hib in the US [54], 
combination HepA/HepB vaccines in Spain [58], and Hib vaccine in Sweden [31]. In a 
number of settings, insufficient funding [22] and loss of donor support [37] resulted in 
vaccine shortages and program interruptions.
A decrease in ambulatory consultations and hospitalizations, disease-related complications, 
and long-term sequelae associated with diseases prevented by the newly introduced vaccines 
was reported from developing and industrialized countries; these led to reductions in health 
care utilization, and in some cases resulted in changes in treatment recommendations 
[31,44,55,59-89] (Table 3). The introduction of PCV in the United States resulted in a 
decrease in the mortality in sickle cell patients; however, guidelines for penicillin 
prophylaxis remained unchanged, because not all pneumococcal serotypes are covered by 
currently available vaccines [90]. In Brazil, all-cause diarrhea costs declined following 
introduction of RV vaccine, but they were not sufficient to offset the costs of program 
implementation [82]. Targeted strategies to vaccinate high-risk populations reduced or 
eliminated racial and ethnic disparities in rates of Hib disease incidence in Israel [91] and 
Australia[92,93] and of pneumococcal disease in the US [94] were decreased or eliminated 
following vaccine introduction. Populations not targeted by the vaccine experienced 
reductions in morbidity and mortality associated with Hib disease [24,39,91,95-100], 
Streptococcus pneumoniae disease [43,83,101-107], meningococcal disease [3,9,108-114], 
hepatitis A [58], hepatitis B [115], typhoid fever [6], rotavirus diarrhea [116-123], human 
papilloma virus infection [124,125], and Japanese encephalitis [47]; these reductions were 
attributed to a herd protective effect.
The introduction of new vaccines has created interest in the development of diversified and 
innovative funding sources and mechanisms for vaccine introduction and sustainability. For 
example, innovative mechanisms such as bridge funding from the Vaccine Fund [49]; World 
Bank, UNICEF, USAID and WHO [42]; and the GAVI alliance [126] have accelerated and 
increased the coverage of new vaccines in low income countries. However, lack of financial 
planning impacted program sustainability in some countries [49,127].
3.8. Leadership and governance
New vaccine introduction impacted various aspects of the vaccine recommendation and 
regulatory processes. In Australia, Belgium, Canada, Chile, Greece, Taiwan, United 
Kingdom, United States, and Uruguay [4,21,27,39,128,129], existing national regulatory 
institutions and advisory committees were used to license and develop recommendations for 
new vaccines. Frequently, subcommittees were formed to develop recommendations for the 
specific vaccine, often in collaboration with academic pediatric and infectious disease 
organizations [39] and disease-specific societies[21,129].
Planning of vaccination campaigns has gone beyond the immunization program to include 
the departments of education, health, and defense; academic institutions and local 
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government [10,21]. In some countries, legislation was enacted to promote vaccine 
implementation or evaluation. For example, Italy had a law requiring routine infant HepB 
vaccination and catch-up vaccination of unvaccinated adolescents [130], and failure to 
comply had the potential to result in the temporary suspension of paternal authority to 
ensure immunization of the minor [131]. In Australia, legislation enabled the establishment 
of a national registry to collect data to assess HPV vaccination coverage [45].
4. Discussion
In this comprehensive review of the published literature, we found that new vaccine 
introduction had a mixed effect on – and often provided opportunities to strengthen – 
existing components of the immunization system. Findings related to impact on the larger 
health system, however, were more limited. Few reviewed papers were designed to evaluate 
impacts on immunization systems or health systems, and information relevant to our review 
was often an incidental finding noted in the discussion section of the papers. In addition, 
most of the reviewed papers were from high- or middle-income countries, whose 
experiences may not represent those from lower-income countries, where the impact related 
to new vaccine introduction – both positive and negative – is likely to be greater. Our 
conclusions, therefore, need to be interpreted in the context of these caveats.
The impact of vaccine introduction differed according to the delivery platform and vaccine 
formulation. When vaccine introduction made use of existing delivery strategies, such as 
with routine infant immunization, costs and impact on staffing were substantially less than 
when vaccines were introduced through newly created platforms. School-based programs 
were documented to be effective platforms for introducing new vaccines to school-aged 
children and adolescents, although additional staff was required, even for existing programs. 
Venues outside the school were sometimes needed to complete the vaccination series in a 
timely fashion. Combination vaccines that added the new antigen or antigens to an existing 
vaccine were less costly and more efficiently introduced than those that required an 
additional injection.
Disruptions in routine vaccination services were reported, related to insufficient on-hand 
stock of the new vaccine when programs commenced, or to global vaccine shortages [132]. 
In low-income countries, service disruption also occurred due to vaccine program funding 
shortfalls, some of which were resolved through partner and donor contributions and 
infrastructure strengthening [22,37]. New vaccine introductions have highlighted existing 
gaps in logistics and cold chain systems; increased cold chain capacity needs were 
commonly reported with the introduction of the early formulations of RV vaccine [56,133]. 
As a result of early introduction experiences with inadequate infrastructure, effective 
vaccine management [134] assessments and regular cold chain inventories are now a 
precondition for new GAVI support in order to assure system readiness for the new vaccine. 
UNICEF has developed a new communication framework for new vaccine introduction that 
emphasizes cold chain readiness, improved adapted vaccines, presentations with reduced 
cold chain volumes, out-of-cold-chain use for outreach sessions, new delivery technologies, 
and enhanced training of health care workers [135]. A comprehensive assessment of cold 
chain capacity should be included in all pre-vaccine introduction assessments.
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Reduced disease incidence following new vaccine introduction, which was primarily 
reported from high-income countries, led to declines in the use of vaccine preventable 
disease-related curative health services (Table 3). Less antibiotic use, reduced antimicrobial 
resistance, and herd immunity extended these benefits to populations not targeted by the 
vaccines. There was some evidence in high-income countries that new vaccine introduction 
was associated with less use of ambulatory and hospital services and reduced costs. An 
important benefit to the health system facilitated by new vaccine introduction has been the 
widespread use of AD syringes and awareness of the importance of injection safety 
[136,137].
In high income countries, existing infrastructures were utilized and often strengthened to 
provide information for vaccine introduction into the early childhood vaccine schedule. In 
some countries, established health information and disease surveillance systems were 
enhanced to collect data for policy development, program advocacy, and impact assessment. 
In other countries, new systems were developed to monitor vaccine safety, vaccine 
effectiveness, and coverage with vaccines administered to age groups beyond early 
childhood, such as HPV vaccine. These new or enhanced systems can be expanded and 
adapted to facilitate introduction of other vaccines, and to improve disease surveillance.
National immunization advisory committees, often referred to as National Immunization 
Technical Advisory Groups (NITAGs), assist Ministries of Health develop evidence-based 
decisions regarding vaccine and immunization policy, including the introduction of new 
vaccines [138,139]. While such committees are more common in high and middle income 
countries, they will likely play increasingly important roles in low-income countries. The 
importance of social mobilization for the public and training and education for health care 
workers was frequently noted. The introduction of new vaccines led to the establishment of 
legislation intended to improve vaccine delivery or program assessment, including 
mandatory newborn vaccination [131] or school entry laws and national vaccine registries.
This review was subject to a number of limitations. Although much of the information about 
the impact of new vaccine introduction is contained in the gray literature [132] only 
published papers were included in this review. We originally proposed to systematically rate 
the quality and strength of evidence presented in the reviewed articles according to the 
GRADE method [140,141]. However, because information related to the impact of new 
vaccine introduction was rarely the main focus of the studies, and because of differences in 
study design and specific data elements collected, we were unable to compare studies or 
evaluate data quality. Because most papers were from high-income countries, it is difficult 
to generalize those experiences to low-income countries, which often have weaker 
infrastructure, and require donor support to fund immunization programs. While changes in 
the immunization and health systems occurred in conjunction with new vaccine 
introduction, we recognize that other health initiatives occurring in the countries during the 
same time period may have also contributed to these changes. Although the majority of 
papers we reviewed were published during the past decade, we also included reports of 
introductions from more than 20 years ago, and these reports may be less relevant to current 
introductions of new vaccines. While it is likely that the impact of vaccine introduction on a 
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country’s existing immunization and health system reflected the underlying system strength, 
evaluating this was beyond the scope of this review.
Donor funding for immunization programs in developing countries is not always consistent 
or predictable; however, in recent years, a number of new immunization funding 
mechanisms have been introduced to provide more stable vaccine financing, and will likely 
facilitate new vaccine introductions in the future. While new vaccine introduction often 
includes an assessment of disease burden and impact on morbidity and mortality, a 
component of future evaluations should include the systematic and objective assessment of 
how the vaccine introduction affects the country’s immunization system and broader health 
system, especially in low-income countries.
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Table 1
Search terms used for systematic literature review of the impact of new vaccine introduction on the 
immunization and health system.
Vaccine search term category
 1 exp *Hepatitis B Vaccines/
 2 exp *Haemophilus Vaccines/
 3 exp *Pneumococcal Vaccines/
 4 exp *Rotavirus Vaccines/
 5 exp *Meningococcal Vaccines/
 6 exp *Yellow Fever Vaccine/
 7 exp *Japanese Encephalitis Vaccines/
 8 exp *Papillomavirus Vaccines/
 9 exp *Typhoid-Paratyphoid Vaccines/
 10 exp *Cholera Vaccines/
 11 (HPV vaccine or HPV vaccines).ab,ti.
 12 (HBV vaccine or HBV vaccines).ab,ti.
 13 (hib vaccine or Hib vaccines).ab,ti.
 14 new vaccine.ab,ti.
 15 new vaccines.ab,ti.
 16 ((under utilised or under-utilised or under utilised or
under-utilised or underutilised or underutilised) and (vaccine
or vaccines)).ab,ti.
Immunization and health system search term category
 17 exp Immunization Programs/
 18 health planning/or health care rationing/or health plan
implementation/or health planning guidelines/or health
planning technical assistance/or health priorities/or health
resources/or national health programs/or exp regional health
planning/
 19 Capacity Building/
 20 exp Inservice Training/
 21 capacity building.ab,ti.
 22 building capacity.ab,ti.
 23 skill development.ab,ti.
24  “delivery of health care”/or health services accessibility/or
healthcare disparities/
 25 equity.ab,ti
 26 “quality of health care”/or clinical competence/or guideline
adherence/or exp “outcome and process assessment (health
care)”/or program evaluation/or quality assurance, health
care/or benchmarking/or clinical audit/or medical audit/or
nursing audit/or total quality management/
 27 health system.ab,ti.
 28 health systems.ab,ti.
 29 (health service or health services).ab,ti.
 30 Health Manpower/
 31 exp “Patient Acceptance of Health Care”/
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 32 (community mobilisation or community mobilisation).ab,ti.
 33 community advocacy.ab,ti.
 34 information systems/or integrated advanced information
management systems/or management information systems/or
ambulatory care information systems/or clinical pharmacy
information systems/or database management systems/or
healthcare common procedure coding system/or “personnel
staffing and scheduling information systems”/
 35 safety.ab,ti.
 36 systems integration/
 37 employee incentive plans/or personnel loyalty/or “personnel
staffing and scheduling”/or personnel turnover/or physician
incentive plans/or “salaries and fringe benefits”/or workload/
 38 Curriculum/
 39 Forecasting/
 40 Group Purchasing/
 41 procurement.ab,ti.
 42 logistics.ab,ti.
 43 cold chain.ab,ti.
 44 financial management/or exp budgets/or fund raising/or risk
management/or financial support/
 45 Health Services/
 46 Health Personnel/
 47 Social Change/
 48 “Organization and Administration”/
 49 Product Surveillance, Postmarketing/
 50 medical waste/or medical waste disposal/
 51 Decision Making, Organizational/
 52 policy making/or advisory committees/
 53 Government Regulation/
 54 stock.ab,ti.
 55 Immunologic Surveillance/
 56 population surveillance/or sentinel surveillance/
57 (strain surveillance or serotype surveillance or virological
surveillance or epidemiological surveillance).ab,ti.
 58 access to services.ab,ti.
 59 (affordability or affordable).ab,ti.
 60 ((timeliness or timely) adj3 vaccination).ab,ti.
 61 delivery strateg*.ab,ti.
 62 integrated disease control.ab,ti.
 63 social mobilization.ab,ti.
 64 (incentiv* adj3 health care worker*).ab,ti.
 65 pre-training.ab,ti.
 66 (in-service training or inservice training).ab,ti.
 67 (career path or career paths).ab,ti.
 68 wages.ab,ti.
 69 supportive supervision.ab,ti.
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 70 data quality.ab,ti.
 71 data collection.ab,ti.
 72 data management.ab,ti.
 73 health management information system.ab,ti.
 74 impact monitoring.ab,ti.
 75 adverse events following immunization.ab,ti.
 76 AEFl.ab,ti.
 77 (post marketing adj3 evaluation).ab,ti.
 78 (demand and supply forecasting).ab,ti.
 79 (demand adj3 forecasting).ab,ti.
 80 (supply adj3 forecasting).ab,ti.
 81 (stock* adj3 manag*).ab,ti.
 82 pooled procurement*.ab,ti.
 83 (effective adj3 vaccine management).ab,ti.
 84 financing.ab,ti.
 85 (vaccine* adj3 price*).ab,ti.
 86 healthy market*.ab,ti.
 87 fiscal space.ab,ti.
 88 budget support.ab,ti.
 89 (donor* adj3 pool*).ab,ti.
 90 SWAp.ab,ti.
 91 opportunity cost*.ab,ti.
 92 (national regulatory agenc* or national immunization
technical advisory group* or national immunisation technical
advisory group* or legislation or governance or accountability
or inter-agency coordinating committee* or interagency
coordinating committee*).ti,ab.
 93 ((treatment adj3 cost*) or (hospitalization adj3 cost*) or
(hospitalisation adj3 cost*) or (norms adj3 standards)).ti,ab.
 94 (storage adj3 capacity).ab,ti.
 95 (storage adj3 volume).ab,ti.
 96 (vaccine* adj3 stor*).ab,ti.
 97 (vaccine* adj3 handl*).ab,ti.
 98 (vaccine* adj5 distribut*).ab,ti.
 99 (vaccine* adj5 transport*).ab,ti.
 100 ((supply or supplies) adj5 (frequen* or interval*)).ab,ti.
 101 logistic*.ab,ti.
 102 ((immunization adj3 expenditure*) or (immunisation adj3
expenditure*)).ab,ti.
 103 exp “health care economics and organizations”/
 104 (economics or legislation jurisprudence).fs.
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Table 2
Literature cited according to World Bank income level, country, and vaccine(s) discussed for vaccines 
introduced 1980–2008.
a
World Bank income 
level
b Country No. of references Vaccine(s)
c
 [Reference]
High Australia 10 Hib [92,93]; HPV [5,16,32,45,124]; PCV [30,106]; RV [123]
Austria 1 RV [117]
Belgium 1 HPV [128]
Canada 14 HepB [18,25]; Hib [24,95]; Influenza [70]; MenPS/Conj
[9,110-112]; PCV [17,43,77,78]; PPV23 [52]
Finland 1 Hib [66]
Germany 2 HAV [12]; PCV [102]
Great Britain 13 Hib [26,62,96]; HPV [23,34]; MenPS/Conj 
[4,7,28,109,113,114];
PCV [72]; PPV23 [33]
Greece 1 HepB [129]
Israel 2 Hib [29,91]
Italy 9 HepB [41,79,89,130,131,137]; PCV [88]; PPV23 [87], RV 
[75]
New Zealand 1 MCV-B [46]
Singapore 1 HBV [19]
Spain 3 HAV/HepB [58]; Hib [97]; MenPS [108]
Sweden 1 Hib [31]
Taiwan 4 HepB [21,80,81,115]
USA 28 Combo (DTP/Hib/HepB/IPV) [54]; Hib [85]; HPV [35]; PCV
[11,59-61,63-65,67,68,71,74,83,86,90,94,101,103,104,107];
PPV23 [76]; RV [86,119-122]
Multiple countries
f 1 Hib [69]
Multiple countries
g,h,i 3 HPV [8,27,125]
Total high income 
country refs. (% of
  total)
96 (75)
Middle Brazil 1 RV [82]
Chile 1 Hib [53]
Cuba 1 Hib [98]
Egypt 1 MenPS [3]
El Salvador 1 RV [118]
Indonesia 1 Typhoid [10]
Mexico 1 RV [116]
Nicaragua 1 RV [51]
Peru 1 HepB [15]
People’s Republic of China HepB [20,36,48]; JE [47]; HAV/JE [38]
Senegal 1 Combo (DTP/Hib/HepB/IPV) [99]
South Africa 2 HepB [44]; Hib [50]
Thailand 1 HepB[13]
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World Bank income 
level




j,k 1 Hib [39]
Multiple countries
l 1 Typhoid [6]
Multiple countries
m 1 RV [56]
Total middle income 
country refs (% of
 total)
21 (16)
Low Ethiopia 1 Combo (DTP/Hib/HB/IPV) [42]
Gambia 1 Hib [55]
Malawi 1 Hib [49]
Zimbabwe 1 HepB [37]





d 18 European countries 1 HPV [57]
50 GAVI-eligible countries 1 HepB & Hib [126]
Americas 1 Hib [41]
Multiple countries
n,o Hib [22,127]
Global 1 HepB [14]
Global
p 1 Hib [100]













Year of vaccine introduction (number [%] of references): 1980–1989 – 14(12%); 1990–1999 – 37 (32%); 2000–2007 – 64 (56%); 115/129 (89%) 
specified studies the year of introduction.
b
Based on Gross National Income (GNI) per capita. Low: <USD1005; middle: USD1006-12,275 (includes lower middle [USD1006-3975] and 
upper middle [USD3976-12,275]); high: >USD12,276.
c
Diphtheria–tetanus–pertussis (DTP), hepatitis A (HAV) vaccine, hepatitis B (HepB) vaccine, Haemophilus influenzae type B (Hib) vaccine, 
human papillomavirus (HPV) vaccine, inactivated polio vaccine (IPV), Japanese Encephalitis (JE), meningococcal polysaccharide (MenPS) 
vaccine, meningococcal conjugate vaccine type B (MCV-B) pneumococcal conjugate vaccine (PCV), 23-valent pneumococcal polysaccharide 
vaccine (PPV-23), and rotavirus (RV) vaccine.
d
Studies done in multiple countries with different World Bank income levels.
e
1 reference identified by the authors and not by the literature search for inclusion is not included in the table [136].
f




USA, Puerto Rico, Canada.
i
Italy & Belgium.

















South Africa & Argentina.
l
Thailand, China, Vietnam, India, Indonesia, Pakistan.
m
Brazil, Ecuador, El Salvador, Panama, Mexico, Nicaragua, Venezuela.
n
Ghana, Mozambique, Tanzania, Lesotho.
o




US, UK, Norway, Netherlands, Germany, Canada, Switzerland, Spain, Australia.
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Table 3
Impact on health care utilization and economic impact (where documented) following new vaccine 
introduction in selected countries.
Vaccine(s) Outcome(s) Country(ies) Reference(s) Reported economic
impact
HepB









savings in acute health


















































and in some cases,
cost-saving [83]
PPV23 Decrease in otitis
media and pneumonia






visit for all-cause and
rotavirus
gastroenteritis
Brazil, Italy, US [60,75,82,84] Decreased curative
health care costs
[60,75,82]; increase




Hepatitis B (HepB), Haemophilus influenzae type b (Hib), pneumococcal conjugate vaccine (PCV), 23-valent pneumococcal polysaccharide 
vaccine (PPV23), rotavirus (RV).
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